KRINTAFEL

This brand name is authorized in United States.

Active ingredients

The drug KRINTAFEL contains one active pharmaceutical ingredient (API):

`1`	Tafenoquine UNII `DL5J0B8VSS` - TAFENOQUINE SUCCINATE
	Tafenoquine is an 8-aminoquinoline antimalarial drug. It is used for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving chloroquine therapy for acute P. vivax infection.
	Read more about Tafenoquine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
KRINTAFEL Film‑coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
US	FDA, National Drug Code	0173-0889

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.